Optimizing HIV Medicines for AIDS-Related Lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy, Infections clinical trials.
This trial helps doctors find the best way to combine HIV medicines (antiretroviral therapy) with lymphoma treatment for people who have both HIV and AIDS-related lymphoma. The goal is to improve your overall care and outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a confirmed HIV infection.
- You have been diagnosed with AIDS-related lymphoma (a lymphoma linked to HIV).
- You are currently receiving treatment for your lymphoma.
- You are willing to take HIV medications and cancer treatment as directed by your doctor.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study keeps a registry (a protected health record database) of adults with lymphoma who also have HIV. The goal is to better understand lymphoma in people with HIV and how they’re diagnosed and followed over time.
This study tests if a two-drug HIV regimen (darunavir/cobicistat plus lamivudine) works as well as a standard three-drug regimen in men whose HIV is already well-controlled. If effective, this could mean taking fewer medications.
This study tests a new drug called glofitamab combined with standard chemotherapy (RCHOP) for people with HIV who have been newly diagnosed with a type of blood cancer called large B-cell lymphoma. The goal is to see if adding glofitamab helps fight the cancer better than chemotherapy alone.
This early-stage trial tests an experimental vaccine designed to train your immune system to fight EBV (Epstein-Barr virus), a virus that can contribute to certain lymphomas in people with HIV. You would receive this vaccine as an add-on treatment if standard chemotherapy hasn't fully controlled your lymphoma.
This study follows adults with well-controlled HIV who are planning to switch to a long-acting HIV medicine given as injections. It may help researchers understand how this approach works for people already stable on current treatment.
This Phase 1 study tests whether a combination of pomalidomide and a dose-adjusted chemotherapy plan (EPOCH), with or without rituximab, can treat certain aggressive B-cell lymphomas in people living with HIV. It aims to find a safe dosing approach and see how well the treatment works for specific lymphoma types or high risk of spread to the brain.
Hear when a new AIDS-related Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.